Your browser doesn't support javascript.
loading
Guide for Combining Primary Tumors for Statistical Analysis in Rodent Carcinogenicity Studies.
Keenan, Charlotte; Al-Haddawi, Muthafar; Bienvenu, Jean-Guy; Bradley, Alys Elizabeth; Brown, Paul; Chen, Hepei; Colman, Karyn; Elwell, Michael; Gatto, Nicholas; Goodman, Dawn; Jacob, Binod; Lanning, Lynda; McKinney, LuAnn; Muhlbradt, Erin; Perry, Rick; Piaia, Alessandro; Potenta, Daniel; Regan, Karen S; Sefing, Benjamin; Thibodeau, Michael; Tibbs-Slone, Erin; Woicke, Jochen; Zwickl, Craig M.
Affiliation
  • Keenan C; C.M. Keenan ToxPath Consulting, Doylestown, Pennsylvania, USA.
  • Al-Haddawi M; Bristol Myers Squibb, New Brunswick, New Jersey, USA.
  • Bienvenu JG; Charles River Laboratories, Senneville, Quebec, Canada.
  • Bradley AE; Charles River Laboratories, Tranent, UK.
  • Brown P; U.S. Food & Drug Administration, Silver Spring, Maryland, USA.
  • Chen H; U.S. Food & Drug Administration, Silver Spring, Maryland, USA.
  • Colman K; Novartis, Cambridge, Massachusetts, USA.
  • Elwell M; Independent Consultant, Apex, North Carolina, USA.
  • Gatto N; Merck & Co., Inc., Kenilworth, New Jersey, USA.
  • Goodman D; Independent Consultant, Providence, Rhode Island, USA.
  • Jacob B; Merck & Co., Inc., Kenilworth, New Jersey, USA.
  • Lanning L; U.S. Food & Drug Administration, Silver Spring, Maryland, USA.
  • McKinney L; U.S. Food & Drug Administration, Silver Spring, Maryland, USA.
  • Muhlbradt E; Medical Science & Computing, Rockville, Maryland, USA.
  • Perry R; Pfizer, Groton, Connecticut, USA.
  • Piaia A; Novartis, Basel, Switzerland.
  • Potenta D; InStem, Winnabow, North Carolina, USA.
  • Regan KS; Regan Path/Tox Services, Kewadin, Michigan, USA.
  • Sefing B; Merck & Co., Inc., Kenilworth, New Jersey, USA.
  • Thibodeau M; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
  • Tibbs-Slone E; Charles River Laboratories, Mattawan, Michigan, USA.
  • Woicke J; Independent Consultant, Scottsdale, Arizona, USA.
  • Zwickl CM; Independent Consultant, Indianapolis, Indiana, USA.
Toxicol Pathol ; 52(1): 13-20, 2024 Jan.
Article in En | MEDLINE | ID: mdl-38445634
ABSTRACT
The Tumor Combination Guide was created at the request of the U. S. Food and Drug Administration (FDA) by a Working Group of biopharmaceutical experts from international societies of toxicologic pathology, the Food and Drug Administration (FDA), and members of the Standard for Exchange of Nonclinical Data (SEND) initiative, to assist pharmacology/toxicology reviewers and biostatisticians in statistical analysis of nonclinical tumor data. The guide will also be useful to study and peer review pathologists in interpreting the tumor data. This guide provides a higher-level hierarchy of tumor types or categories correlating the tumor names from the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) publications with those available in the NEOPLASM controlled terminology (CT) code list in SEND. The version of CT used in a study should be referenced in the nonclinical study data reviewer's guide (SDRG) (section 3.1) of electronic submissions to the FDA. The tumor combination guide instructions and examples are in a tabular format to make informed decisions for combining tumor data for statistical analysis. The strategy for combining tumor types for statistical analysis is based on scientific criteria gleaned from the current scientific literature; as SEND and INHAND terminology and information evolve, this guide will be updated.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Carcinogenicity Tests Limits: Animals Country/Region as subject: America do norte Language: En Journal: Toxicol Pathol Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Carcinogenicity Tests Limits: Animals Country/Region as subject: America do norte Language: En Journal: Toxicol Pathol Year: 2024 Type: Article Affiliation country: United States